Has Paxlovid (nirmatrelvir + ritonavir) been associated with true muscle weakness, including neurologic, rheumatologic, medication‑ or toxin‑related, and infectious etiologies in a patient who experienced extensive problems after taking the medication?

Paxlovid Has Not Been Directly Associated with True Muscle Weakness

The available evidence does not establish Paxlovid (nirmatrelvir/ritonavir) as a direct cause of true muscle weakness from neurologic, rheumatologic, medication-related, or infectious etiologies. The FDA label for Paxlovid does not list muscle weakness as an adverse reaction, and the most commonly reported adverse events in clinical trials were dysgeusia (5%) and diarrhea (3%) 1.

Understanding the Clinical Context

The patient's "extensive problems" after taking Paxlovid require careful differential diagnosis, as several mechanisms could explain their symptoms:

Drug-Drug Interactions (Most Likely Culprit)

Ritonavir is a potent CYP3A4 inhibitor that can cause severe, life-threatening adverse reactions through drug interactions 1. The FDA explicitly warns that the most commonly reported concomitant medications resulting in serious adverse reactions were calcineurin inhibitors (tacrolimus, cyclosporine) and calcium channel blockers 1.

• If your patient was taking tacrolimus: Multiple case reports document generalized weakness as a presenting symptom of tacrolimus toxicity induced by Paxlovid 2, 3. One case specifically described "generalized weakness" in the emergency department that was ultimately attributed to Paxlovid-tacrolimus interaction 2.

• If your patient was taking statins: The FDA label contraindicates lovastatin and simvastatin with Paxlovid due to risk of myopathy 1. Statins are among the most frequently managed interactions (17.7% of all interacting medications in one large series) 4.

Neurological Adverse Events (Less Common but Documented)

Real-world pharmacovigilance data shows Paxlovid is associated with neurological adverse events, though headache, dysgeusia, and anosmia are the predominant symptoms—not true muscle weakness 5. A 2025 FDA adverse event analysis found Paxlovid had a 2.27-fold higher signal for neurological events compared to other COVID-19 drugs, but these were primarily sensory disturbances 5.

COVID-19 Itself Can Cause Muscle Weakness

COVID-19 infection independently causes respiratory muscle weakness through viral-induced myopathy, with 88% of patients showing respiratory muscle weakness 5 months post-infection and 65% of non-hospitalized patients affected 6. The virus can infiltrate diaphragm myofibers and cause fibrosis 6. This is critical: the patient's symptoms may be from COVID-19 rather than Paxlovid.

Diagnostic Approach for Your Patient

Since true muscle weakness is not a recognized direct effect of Paxlovid, evaluate alternative etiologies systematically:

1. Review All Concomitant Medications Immediately

• Check for CYP3A4 substrates, particularly:
  • Immunosuppressants (tacrolimus, cyclosporine)
  • Statins (especially lovastatin, simvastatin)
  • Calcium channel blockers
  • Any drug listed in the FDA contraindications 1

2. If Muscle Weakness is Present, Obtain:

• CK, AST, ALT, LDH, aldolase to evaluate for myositis 7, 8
• Troponin and ECG to exclude myocardial involvement 7, 8
• ESR, CRP for inflammatory markers 7, 8
• Therapeutic drug monitoring if patient takes tacrolimus, cyclosporine, or other narrow therapeutic index drugs 1
• Thyroid function, vitamin D, creatinine to exclude other causes of weakness 9

3. Perform Focused Neurologic and Rheumatologic Examination

• Assess muscle strength systematically (proximal vs. distal)
• Look for dermatomyositis skin findings 7, 8
• True muscle weakness is more typical of myositis than pain alone 7
• Consider EMG, MRI of affected limbs if diagnosis uncertain 7, 8

4. Consider COVID-19-Related Muscle Effects

• Respiratory muscle weakness with dyspnea on exertion 6
• Post-viral fatigue syndrome
• Phrenic nerve injury (rare but documented) 6

Critical Pitfalls to Avoid

1. Do not assume Paxlovid directly caused muscle weakness without investigating drug interactions first—the ritonavir component is the likely culprit through elevation of other myotoxic drugs 1, 2, 3.

2. Do not overlook statin-induced myopathy—if the patient continued statins during Paxlovid, this is a high-risk scenario 9, 1.

3. Do not attribute all symptoms to Paxlovid when COVID-19 itself causes persistent neuromuscular effects 6.

4. If CK is elevated ≥3× ULN with weakness, initiate prednisone 0.5-1 mg/kg and refer to rheumatology/neurology urgently 7, 8.

Management Based on Findings

• If drug interaction identified: Discontinue offending agent, provide supportive care, consider therapeutic drug monitoring 1, 3
• If myositis confirmed: Follow immune-related adverse event guidelines with corticosteroids and specialist referral 7, 8
• If COVID-19-related muscle weakness: Consider respiratory muscle testing and rehabilitation 6

The bottom line: Paxlovid's ritonavir component causes problems through drug interactions, not through direct muscle toxicity. Your investigation should focus on what other medications were on board and whether COVID-19 itself is the underlying cause of weakness.